Xin Lang Zheng Quan·2025-11-06 01:29Core Viewpoint - Guangdong Wannianqing Pharmaceutical Co., Ltd. is experiencing a decline in revenue and net profit, while its financing activities indicate a low level of market engagement and high short-selling potential. Group 1: Financial Performance - As of September 30, 2023, the company reported a revenue of 228 million yuan, a year-on-year decrease of 0.14% [2] - The net profit attributable to the parent company was -8.13 million yuan, representing a year-on-year decrease of 157.65% [2] Group 2: Shareholder and Market Activity - The number of shareholders decreased to 11,400, a reduction of 7.18% compared to the previous period [2] - The average number of circulating shares per shareholder increased to 13,994 shares, an increase of 7.74% [2] Group 3: Financing and Margin Trading - On November 5, 2023, the company had a financing buy-in amount of 3.50 million yuan, with a net financing buy of 944,100 yuan [1] - The total financing and margin trading balance was 53.72 million yuan, accounting for 1.93% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company had no short-selling activity on November 5, 2023, with a short-selling balance of 0 yuan, indicating a high level of short-selling potential compared to the 90th percentile level over the past year [1] Group 4: Dividend Distribution - Since its A-share listing, the company has distributed a total of 65.60 million yuan in dividends, with 40 million yuan distributed over the past three years [3]